Scholarlink

<p>The number of long-term survivors after pancreatic cancer is increasing due to recent advances in diagnosis and multidisciplinary treatments. However, the effectiveness of pulmonary metastasectomy remains uninvestigated. This study aims to evaluate the oncological outcomes of pulmonary metastasectomy in pancreatic cancer and to identify potential prognostic factors affecting survival. Patients undergone pulmonary metastasectomy, with previous radical surgery on pancreatic cancer and no evidence of disease in other organs, were selected. Therefore, clinical data of 56 patients from 7 high-volume centers were retrospectively analyzed. Long-term oncological outcomes and prognostic factors were evaluated. Five- and 10-year OS from pancreatectomy were 76% and 42%, respectively. Multivariable analysis confirmed as negative prognostic factors: male sex (HR = 25.7, 95%CI 3.5–190.2, p = 0.001), major lung metastasis diameter &gt; 1.3&#xa0;cm (HR = 50.8, 95%CI 3.7–692.2, p = 0.003) and synchronous metastases with primary cancer (HR = 61.2, 95%CI 3.1–1203.2, p = 0.007). The 5-year DFS from pancreatectomy and first lung metastasis was 13%, with a median of 32&#xa0;months. The only prognostic factor affecting DFS was pN2 pancreatic disease (p = 0.008) at multivariable analysis. The 1-year DFI between first and second lung metastasis was 9%, with a median of 11&#xa0;months. The 5-year OS from the first pulmonary metastasectomy was 47%. The main prognostic factors at univariable analysis were pT (p &lt; 0.001), RT/CT neoadjuvant or adjuvant therapy after pancreatectomy (p = 0.01), major lung metastasis diameter &gt; 1.3&#xa0;cm (p = 0.04) and reiterative lung metastasectomy for pulmonary recurrence (p = 0.04). No factor was confirmed in the multivariable analysis. Pulmonary metastasectomy after radical surgery for pancreatic cancer seems to be a valuable treatment in well-selected patients. Reiterative pulmonary surgery may also represent a potential therapeutic option in carefully selected cases.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer

  • 期刊论文

  • 发表日期：

    2026年4月4日

查看全文
  • Dania Nachira,
  • Giuseppe Calabrese,
  • Luca Bertolaccini,
  • Elisa Meacci,
  • Maria Teresa Congedo,
  • Pierluigi Novellis,
  • Angela De Palma,
  • Rosalia Romano,
  • Pietro Bertoglio,
  • Gianmaria Ferretti,
  • Jessica Evangelista,
  • Annalisa Campanella,
  • Matteo Chiari,
  • Francesca Misceo,
  • Francesco De Blasi,
  • Mariangela Valentini,
  • Leonardo Valentini,
  • Jury Brandolini,
  • Marco Taurchini,
  • Giuseppe Bogina,
  • Giulia Veronesi,
  • Giuseppe Marulli,
  • Lorenzo Spaggiari,
  • Stefano Margaritora

摘要

The number of long-term survivors after pancreatic cancer is increasing due to recent advances in diagnosis and multidisciplinary treatments. However, the effectiveness of pulmonary metastasectomy remains uninvestigated. This study aims to evaluate the oncological outcomes of pulmonary metastasectomy in pancreatic cancer and to identify potential prognostic factors affecting survival. Patients undergone pulmonary metastasectomy, with previous radical surgery on pancreatic cancer and no evidence of disease in other organs, were selected. Therefore, clinical data of 56 patients from 7 high-volume centers were retrospectively analyzed. Long-term oncological outcomes and prognostic factors were evaluated. Five- and 10-year OS from pancreatectomy were 76% and 42%, respectively. Multivariable analysis confirmed as negative prognostic factors: male sex (HR = 25.7, 95%CI 3.5–190.2, p = 0.001), major lung metastasis diameter > 1.3 cm (HR = 50.8, 95%CI 3.7–692.2, p = 0.003) and synchronous metastases with primary cancer (HR = 61.2, 95%CI 3.1–1203.2, p = 0.007). The 5-year DFS from pancreatectomy and first lung metastasis was 13%, with a median of 32 months. The only prognostic factor affecting DFS was pN2 pancreatic disease (p = 0.008) at multivariable analysis. The 1-year DFI between first and second lung metastasis was 9%, with a median of 11 months. The 5-year OS from the first pulmonary metastasectomy was 47%. The main prognostic factors at univariable analysis were pT (p < 0.001), RT/CT neoadjuvant or adjuvant therapy after pancreatectomy (p = 0.01), major lung metastasis diameter > 1.3 cm (p = 0.04) and reiterative lung metastasectomy for pulmonary recurrence (p = 0.04). No factor was confirmed in the multivariable analysis. Pulmonary metastasectomy after radical surgery for pancreatic cancer seems to be a valuable treatment in well-selected patients. Reiterative pulmonary surgery may also represent a potential therapeutic option in carefully selected cases.

Graphical abstract